Anthera Pharmaceuticals, Inc. (ANTH) Research

Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.

Market snapshot

Symbol
ANTH
Price
$0.00
Day change
0.00%
Market cap
$26.2K
P/E ratio
-0.00x
52-week range
0.0001-0.001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Comera Life Sciences Holdings, Inc. (CMRA)
  • Cotinga Pharmaceuticals Inc. (COTQF)
  • GlobeImmune, Inc. (GBIM)
  • Neurobiological Technologies, Inc. (NTII)
  • OncoVista Innovative Therapies, Inc. (OVIT)
  • PhaseRx, Inc. (PZRXQ)
  • Sienna Biopharmaceuticals, Inc. (SNNAQ)
  • SheerVision, Inc. (SVSO)

Recent insider activity

  • THOMPSON JOHN CRAIG — A-Award (1847074 shares) on 2018-01-05
  • SHANAHAN WILLIAM R JR — A-Award (567876 shares) on 2018-01-05
  • TRUEX PAUL F — A-Award (84705 shares) on 2018-01-05
  • Thompson David E. — A-Award (84705 shares) on 2018-01-05
  • Sager Philip — A-Award (84705 shares) on 2018-01-05

Open Anthera Pharmaceuticals, Inc. (ANTH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.